Schattner Ami
The Faculty of Medicine, Hebrew University Hadassah Medical School, Ein Kerem, Jerusalem 91120, Israel.
Pathogens. 2024 Aug 7;13(8):667. doi: 10.3390/pathogens13080667.
CMV is a ubiquitous DNA virus that establishes infection and results in 40-100% seropositivity. Viral replication occurs following an acquired primary infection (or reinfection) or by the reactivation of life-long latency. In immunocompetent patients, CMV infection is mostly asymptomatic or mild and self-limited. However, an extensive review of the literature published up to April 2024 reveals that despite immunocompetence, CMV can cause a very large variety of clinical syndromes in any part of the gastrointestinal tract (the most common pattern), the central or peripheral nervous system, and the eyes, as well as hematological, pulmonary, cardiac, and cutaneous disease. Not uncommonly, more than one system is involved, and though the disease is often self-limited, treatment with intravenous ganciclovir or oral valganciclovir may be required, and in isolated cases, fatalities may occur. Thus, a potential CMV infection should be considered in the differential of myriad syndromes in non-immunocompromised patients. Associated systemic symptoms (fever, sweats, and weight loss), lymphocytosis, and hepatitis are not uncommon and can be a useful clue. Some populations, such as critically ill patients in intensive care, pregnant women, elderly patients, and those with inflammatory bowel disease, may be more susceptible. Moreover, the potential of past, latent CMV infection (i.e., CMV seropositivity) to be associated with significant cardiovascular morbidity and all-cause mortality years later is intriguing and requires further study. All these data indicate the outstanding importance of developing a vaccine against CMV, which hopefully will become available in the foreseeable future. Meanwhile, a solid diagnosis of active CMV infection can be quickly established (or ruled out) by widely available serology tests and PCR amplification, and clinicians in all disciplines need to be more aware of the diverse guises of CMV infection and remember to consider it in any host, including an immunocompetent one.
巨细胞病毒(CMV)是一种普遍存在的DNA病毒,可引发感染,导致40%-100%的血清学阳性率。病毒复制发生在获得性原发性感染(或再感染)后,或终身潜伏状态的重新激活后。在免疫功能正常的患者中,CMV感染大多无症状或症状轻微且为自限性。然而,截至2024年4月发表的文献的广泛综述显示,尽管免疫功能正常,但CMV可在胃肠道的任何部位(最常见模式)、中枢或外周神经系统、眼睛以及血液、肺部、心脏和皮肤疾病中引发各种各样的临床综合征。通常不止一个系统受累,尽管疾病往往是自限性的,但可能需要静脉注射更昔洛韦或口服缬更昔洛韦进行治疗,在个别情况下可能会导致死亡。因此,在非免疫功能低下患者出现多种综合征的鉴别诊断中应考虑潜在的CMV感染。相关的全身症状(发热、盗汗和体重减轻)、淋巴细胞增多和肝炎并不少见,可能是有用的线索。一些人群,如重症监护病房的重症患者、孕妇、老年患者以及患有炎症性肠病的患者,可能更易感染。此外,过去潜伏的CMV感染(即CMV血清学阳性)多年后与显著的心血管发病率和全因死亡率相关的可能性很有趣,需要进一步研究。所有这些数据表明开发针对CMV的疫苗具有突出的重要性,有望在可预见的未来问世。与此同时,通过广泛可用的血清学检测和PCR扩增可以快速确立(或排除)活动性CMV感染的可靠诊断,所有学科的临床医生都需要更加了解CMV感染的多种表现形式,并记住在任何宿主中都要考虑到它,包括免疫功能正常的宿主。